Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- 6 The application of high-throughput analyses to cancer diagnosis and prognosis
- 7 Cancer proteomics
- 8 Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
- 9 In situ techniques for protein analysis in tumor tissue
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- Index
- References
9 - In situ techniques for protein analysis in tumor tissue
from Part 1.2 - Analytical techniques: analysis of RNA
Published online by Cambridge University Press: 05 February 2015
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- 6 The application of high-throughput analyses to cancer diagnosis and prognosis
- 7 Cancer proteomics
- 8 Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
- 9 In situ techniques for protein analysis in tumor tissue
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- Index
- References
Summary
Overview of the analytical techniques
Assessment of protein expression is a vital part of diagnostic pathology routinely used in addition to morphologic evaluation for establishing a definite diagnosis and histological subclassification of tumors. Immunohistochemistry (IHC)-based technologies have expanded the spectrum of clinical applications beyond histological diagnosis towards identifying prognostic biomarkers and guiding selection of patients for personalized treatment. This chapter reviews the current analytical techniques for protein detection.
Chromagenic immunohistochemistry
IHC selectively detects specific proteins in tissue and provides complementary diagnostic information to morphological observations; IHC has thus become a routine technique for diagnostic purposes (a subset of popular IHC-assessed proteins contributing to tumor diagnosis, characterization, and prognosis are summarized in Table 9.1). In contrast, it has also been used as a companion diagnostic test to predict response to specific therapies. The classic examples of this usage are estrogen receptor (ER; 1) and human epidermal growth factor receptor 2 (HER2; 2) in breast cancer. Advantages of IHC include application in formalin-fixed paraffin-embedded (FFPE) tissue, wide availability, low cost, and simplicity when coupled with a pathologist's assessment at the light microscope. However, conventional IHC can be restricted by low sensitivity or differences in sample preparation and fixation (3,4). These issues have been addressed by developing signal-amplification techniques and antigen retrieval methods, respectively (5). In principle, IHC requires at least an antibody detecting the antigen of interest that is linked to an enzymatic system (most commonly peroxidase or alkaline phosphatase), used to visualize the site of antigen–antibody reaction.
- Type
- Chapter
- Information
- Molecular OncologyCauses of Cancer and Targets for Treatment, pp. 76 - 84Publisher: Cambridge University PressPrint publication year: 2013